Abstract:One of the neuropathological hallmarks of Alzheimer's disease is the presence of β-amyloid (Aβ)-containing neuritic plaques. Aβ is produced by the proteolytic cleavage of the amyloid precursor protein by β- and γ-secretase enzymes. Thus, inhibition of β-secretase (BACE1) is a promising disease modifying approach for the treatment of Alzheimer's disease. Identification of orally-bioavailable, CNS-active small molecule BACE inhibitors is challenging. SCH 785532 is a novel, potent, non-peptidic, orally available and brain penetrant BACE inhibitor. Following acute administration in pre-plaque transgenic CRND8 (TgCRND8) mice over-expressing human amyloid precursor protein with two familial Alzheimer's disease mutations, SCH 785532 produced robust inhibition of plasma Aβ but only modestly reduced cortical Aβ levels. This study sought to determine if chronic treatment with this BACE inhibitor would reduce cortical Aβ levels as well as to assess the disease modifying potential of chronic BACE inhibition as measured by a reduction in plaque deposition and/or improvement in cognitive performance. Beginning at 6 weeks of age (pre-plaque), TgCRND8 mice were treated with vehicle or SCH 785532 (100 mg/kg/day, in diet) for 6, 12, 18 or 24 weeks (well into the plaque deposition period). This dose given in diet provided relatively constant exposure and robust inhibition of plasma Aβ. Following 12-24 weeks of treatment, SCH 785532 reduced total guanidine extracted cortical Aβ40 and Aβ42 levels by 30%. While total β-amyloid plaque burden was not dramatically changed with SCH 785532 treatment, mature Thioflavine S positive fibrillar Aβ containing plaques were reduced by 35% after 24 weeks of treatment. Increased microglia reactivity observed around Aβ plaques was not noticeably reduced by 24 weeks of treatment with SCH 785532. TgCRND8 mice treated with vehicle did not perform as well as non-transgenic vehicle-treated mice in the Morris water maze and 24 weeks of treatment with SCH 785532 moderately improved performance of the transgenic mice in this cognition model. Overall, the results of this study demonstrate that chronic BACE inhibition reduced brain Aβ levels, delayed the maturation of amyloid plaques, improved cognitive function and was well tolerated. This study provides support that inhibition of BACE may have disease-modifying potential in the clinic.

Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

Chronic Treatment with the Γ-Secretase Inhibitor LY-411,575 Inhibits Β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation*

In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea Racemosa.

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer's Disease

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer’s Disease

Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

((<i>E</i>)-<i>N</i>-(4-(((2-Amino-5-phenylpyridin-3-yl)imino)methyl)pyr idin-2-yl)cyclopropanecarboxamide) Ameliorated A<sub>1-42</sub>-Induced Alzheimer's Disease in SD Rats by Inhibiting Oxidative Stress and Apoptosis

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.

P4‐687: SUBSTRATE BINDING INHIBITS Γ‐secretase CLEAVAGE OF AMYLOID PRECURSOR PROTEIN

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study